Gender and clinical trials: is the Regulation n. 536/2914 (EU) a missed opportunity?
DOI:
https://doi.org/10.15168/2284-4503-2478Keywords:
Gender, clinical trials, EU Regulation 536/2014, health inequalities, gender-specific medicineAbstract
This paper aims at discussing the Regulation n. 536/2914 (EU) under a gendered perspective. In the first part the article will discuss the importance of the gender-specific medicine approach and its latest applications and implications in the field of clinical trials. After this, the relevant norms in the Regulation will be highlighted and discussed. A critique will be provided, after having analyzed some relevant national experiences (USA, Canada, Italy, in particular). In the last paragraph some suggestions for further implementation will be discussed.
Downloads
Published
2022-12-23
Issue
Section
Focus on
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
1.
Gender and clinical trials: is the Regulation n. 536/2914 (EU) a missed opportunity?. BioLaw [Internet]. 2022 Dec. 23 [cited 2026 Jul. 7];(4):251-76. Available from: https://teseo-ojs35-test.archicoop.it/biolaw/article/view/2478
